HomeNDC LookupDrug shortages › Triamcinolone Acetonide Injection

Triamcinolone Acetonide Injection shortage (resolved)

Triamcinolone Acetonide Injection is not in an active FDA shortage right now. The most recent status on record was “Resolved”. This page is kept for history. This page was last refreshed from FDA data on Sep 22, 2026.

Resolved Ophthalmology 1 product lasted 1,768 days · 4.8 yr First posted Sep 27, 2021 Updated Jul 31, 2026
Here’s the bottom line

Triamcinolone Acetonide Injection is not in an active FDA shortage right now (last status: “Resolved”) — confirm current availability with your pharmacy.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
1,768
Days in shortage
131
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 22, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Triamcinolone Acetonide Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
Other 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Triamcinolone Acetonide Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Novartis Pharmaceuticals Corporation Bausch & Lomb Incorporated
See all other options & details →
Shortage timeline
  1. Jul 31, 2026
    Shortage resolved
    FDA no longer lists this as an active shortage.
  2. Sep 27, 2021
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Harrow Eye, LLC 📞 (615) 733-4734 1 NDC click to expand
Status NDC / product Strength / size Availability Related information Reason
Resolved Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01) NDC 82667-0800-01

These rows are manufacturer reports to the FDA for Triamcinolone Acetonide Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Triamcinolone Acetonide Injection? options further down this page.

Why is Triamcinolone Acetonide Injection in shortage?

Harrow Eye, LLC has reported this product to the FDA's shortage list, but they have not shared a specific public reason for why it's there. That kind of limited detail does happen sometimes — manufacturers aren't always required to explain the "why" beyond filing the report.

What I can tell you is that according to this report, Harrow Eye's Triesence (triamcinolone acetonide injection, 40 mg/1 mL) is currently listed as available, which is a good sign. This report reflects only what Harrow Eye has filed with the FDA — it doesn't speak to other manufacturers of this medicine.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Triamcinolone Acetonide Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Triamcinolone Acetonide Injection?

Triamcinolone Acetonide Injection is currently on the FDA drug-shortage list. I want to walk you through what this means for the strength you may use.

The one strength covered here, 40 mg/1 mL, still has an available source. There are no strengths of this injection listed as having no available source right now. In other words, every currently listed version of this product has supply reported.

This shortage has been recorded for over a year, but the picture remains steady: the single manufacturer on this record, Harrow Eye, LLC, reports its 40 mg/1 mL product (Triesence) as available, and none of the listed products are marked unavailable. That is a reassuring sign for continued access.

Here is what I suggest:

  • Do not stop, skip, or change your doses on your own.
  • Since your strength still has supply, ask your pharmacy to order it — pharmacies can check wholesalers and manufacturers.
  • If needed, your pharmacy may also be able to source the same medicine from another maker, such as the Triesence or Xipere products listed on this page, though these may not be in local stock.
  • If you cannot find your exact product, ask your prescriber or pharmacist about options.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle these calls. This is general national information and may not match your local pharmacy's actual stock.

See “Where else can I get Triamcinolone Acetonide Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Triamcinolone guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Triamcinolone guide →

Where else can I get Triamcinolone Acetonide Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Triamcinolone Acetonide Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Triesence TRIAMCINOLONE ACETONIDE 40 mg/mL Injection, Suspension · Ophthalmic Novartis Pharmaceuticals Corporation 00078-0897-78
Xipere TRIAMCINOLONE ACETONIDE 40 mg/mL Injection, Suspension · Ophthalmic Bausch & Lomb Incorporated 24208-0040-01

Other drugs in the same treatment class

These are different medicines — not other versions of Triamcinolone Acetonide Injection — that fall in the same broad treatment class (eye anti-inflammatory agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 063905
GCN 99617
HICL code 035556
Ingredient (HICL) Triamcinolone Acetonide/Pf
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6P
Therapeutic class — specific (HIC3) Eye Anti-Inflammatory Agents
AHFS code 52:08.08.00
AHFS class Corticosteroids (Eent)
FDB label name TRIESENCE 40 MG/ML VIAL
FDB brand name Triesence
Legend status F — Federal legend — prescription drug or device
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other ophthalmology shortages

Triamcinolone Acetonide Injection shortage FAQs

Is Triamcinolone Acetonide Injection in shortage?
No — Triamcinolone Acetonide Injection is not in an active FDA shortage right now (last status on record: “Resolved”). It is kept here for history.
Which products are affected?
Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01) (NDC 82667-0800-01). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Triamcinolone Acetonide Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Triamcinolone Acetonide somewhere?
Other manufacturers (Novartis Pharmaceuticals Corporation, Bausch & Lomb Incorporated) still market it and have not reported a shortage. See “Where else can I get Triamcinolone Acetonide Injection?” above — stock still varies by pharmacy.
What should I do if I take Triamcinolone Acetonide Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Triamcinolone Acetonide Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages